Observations on the systemic effect of topical clobetasol propionate (Dermovate).

J A Carruthers, P J August, R C Staughton

Index: Br. Med. J. 4(5990) , 203-4, (1975)

Full Text: HTML

Abstract

Topical application of clobetasol propionate in a strength of 0-05% in cream or ointment (Dermovate) suppressed the hypothalamic-pituitary-adrenal axis in both normal people and patients with diseased skin. In normal people the 9 am serum cortisol level was suppressed when between 45 and 90 g was applied weekly. Insulin stress test results in patients with diseased skin showed an abnormally small response after long-term application of similar amounts. We conclude that long-term administration should be restricted to less than 50 g a week.


Related Compounds

Related Articles:

Curcumin relieves TPA-induced Th1 inflammation in K14-VEGF transgenic mice.

2015-04-01

[Int. Immunopharmacol. 25(2) , 235-41, (2015)]

Topical steroids for chronic wounds displaying abnormal inflammation.

2013-05-01

[Ann. R. Coll. Surg. Engl. 95(4) , 291-6, (2013)]

Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.

2012-11-01

[Journal. of. Drugs in. Dermatology. 11(11) , 1348-54, (2012)]

Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis.

2012-02-01

[Cutis. 89(2) , 89-94, (2012)]

Influence of the type of vegetable oil on the drug release profile from lipid-core nanocapsules and in vivo genotoxicity study.

2014-11-01

[Pharm. Dev. Technol. 19(7) , 789-98, (2014)]

More Articles...